Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode

PHASE4CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Schizophrenia
Interventions
DRUG

early initiation of treatment with Risperdal Consta

25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.

DRUG

routine initiation of treatment with Risperdal Consta

25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.

Trial Locations (31)

Unknown

Copenhagen

Glostrup Municipality

Hjørring

Kolding

Helsinki

Vantaa

Bar-le-Duc

Beaupuy

Clermont-Ferrand

Colmar

La Seyne-sur-Mer

Mont-Saint-Martin

Athens

Chania

Thessalonikis

Tripoli

Bat Yam

Pardesiyya

Petah Tikva

Levanger

Ljubljana

Danderyd

Gothenburg

Huddinge

Stockholm

Trollhättan

Oetwil

Sankt Urban

Zurich

London

Norfolk

All Listed Sponsors
lead

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

NCT00216671 - Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode | Biotech Hunter | Biotech Hunter